Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
Authors
Keywords
-
Journal
Current HIV/AIDS Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-30
DOI
10.1007/s11904-019-00480-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Switching strategies in the recent era of antiretroviral therapy
- (2019) Paula Prieto et al. Expert Review of Clinical Pharmacology
- Is there a safety signal for dolutegravir and integrase inhibitors during pregnancy?
- (2019) Laurent Chouchana et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle
- (2019) Rachel Van Duyne et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
- (2019) Jessica Radzio-Basu et al. Nature Communications
- Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice
- (2019) Prasanta K. Dash et al. Nature Communications
- HIV-1 integrase inhibitors that are broadly effective against drug-resistant mutants
- (2018) Steven J. Smith et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
- (2018) Tian Zhou et al. BIOMATERIALS
- The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor
- (2018) B. Narasimhulu Naidu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cellular and molecular mechanisms of HIV-1 integration targeting
- (2018) Alan N. Engelman et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
- (2018) Ingeborg E A Wijting et al. JOURNAL OF INFECTIOUS DISEASES
- The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors
- (2018) Hanh T Pham et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
- (2018) Steven J. Smith et al. Retrovirology
- Creation of a long-acting nanoformulated dolutegravir
- (2018) Brady Sillman et al. Nature Communications
- Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain
- (2018) Upal Roy et al. Scientific Reports
- Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution
- (2018) Bhavesh D. Kevadiya et al. Theranostics
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress
- (2018) J. Rafael Montenegro-Burke et al. MOLECULAR NEUROBIOLOGY
- Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
- (2018) Rebecca Zash et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques
- (2018) JoEllyn McMillan et al. AIDS
- DeepHINT: understanding HIV-1 integration via deep learning with attention
- (2018) Hailin Hu et al. BIOINFORMATICS
- Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase
- (2017) Jing Tang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Dual antiretroviral therapy for HIV infection
- (2017) Vicente Soriano et al. Expert Opinion On Drug Safety
- Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis
- (2017) Jose Echecopar-Sabogal et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients
- (2017) Aubin J. Nanfack et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- HIV drug resistance against strand transfer integrase inhibitors
- (2017) Kaitlin Anstett et al. Retrovirology
- Picking the Survivor! CRISPR Reveals HIV Dependency Factors
- (2017) Kerstin Schott et al. TRENDS IN MICROBIOLOGY
- Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
- (2017) Isabelle Malet et al. mBio
- Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
- (2017) Ingeborg Wijting et al. Lancet HIV
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
- (2017) Paul E Sax et al. Lancet HIV
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
- (2016) Manuel Tsiang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Advancements in nano-enabled therapeutics for neuroHIV management
- (2016) Ajeet Kaushik et al. International Journal of Nanomedicine
- Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake
- (2015) Emilie Elliot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
- (2015) David A Margolis et al. LANCET INFECTIOUS DISEASES
- Single-Cell and Single-Cycle Analysis of HIV-1 Replication
- (2015) Mowgli Holmes et al. PLoS Pathogens
- Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
- (2015) Jean-Michel Molina et al. Lancet HIV
- Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
- (2014) Craig Fenwick et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
- (2014) Tomokazu Yoshinaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process
- (2014) Dominga Rogolino et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
- (2014) Samir Mitragotri et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
- (2014) Lee D. Fader et al. ACS Medicinal Chemistry Letters
- Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202
- (2013) Philip M. Grant et al. HIV CLINICAL TRIALS
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV
- (2013) Bhavik M. Shah et al. PHARMACOTHERAPY
- Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens
- (2012) Carolina Garrido et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing
- (2012) Daniele Armenia et al. JOURNAL OF INFECTIOUS DISEASES
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
- (2012) N. M. Archin et al. NATURE
- The structural biology of HIV-1: mechanistic and therapeutic insights
- (2012) Alan Engelman et al. NATURE REVIEWS MICROBIOLOGY
- Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes
- (2011) Fernanda Scopelliti et al. ANTIVIRAL RESEARCH
- In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
- (2011) Nicolas A. Margot et al. ANTIVIRAL RESEARCH
- Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK
- (2011) Jürgen K. Rockstroh et al. CLINICAL INFECTIOUS DISEASES
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- Structural biology of retroviral DNA integration
- (2011) Xiang Li et al. VIROLOGY
- Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates
- (2010) L. Van Wesenbeeck et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment
- (2010) Jia Liu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA
- (2010) Christopher A Koczor et al. Expert Opinion on Drug Metabolism & Toxicology
- Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor
- (2010) T. Bar-Magen et al. JOURNAL OF VIROLOGY
- Retroviral intasome assembly and inhibition of DNA strand transfer
- (2010) Stephen Hare et al. NATURE
- Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
- (2010) S. Hare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Raltegravir
- (2009) Jamie D Croxtall et al. DRUGS
- Raltegravir
- (2009) Jamie D. Croxtall et al. DRUGS
- Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
- (2009) Mayte Coiras et al. NATURE REVIEWS MICROBIOLOGY
- Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
- (2009) Paul E. Sax et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
- (2009) Erik Serrao et al. Retrovirology
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro
- (2008) I. Malet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lack of a Significant Drug Interaction between Raltegravir and Tenofovir
- (2008) L. A. Wenning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants
- (2008) M KOBAYASHI et al. ANTIVIRAL RESEARCH
- The Terminal (Catalytic) Adenosine of the HIV LTR Controls the Kinetics of Binding and Dissociation of HIV Integrase Strand Transfer Inhibitors
- (2008) David R. Langley et al. BIOCHEMISTRY
- Anti-infectives Clinical progress of HIV-1 integrase inhibitors
- (2008) Laith Q Al-Mawsawi et al. EXPERT OPINION ON EMERGING DRUGS
- HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
- (2008) B. Roquebert et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
- (2008) Vincenzo Summa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tetrameric Structure of a Serine Integrase Catalytic Domain
- (2008) Peng Yuan et al. STRUCTURE
- Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation
- (2007) Marian Iwamoto et al. JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now